Tango Therapeutics, Inc. (TNGX) Key Metrics
TNGX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $3.72B
- Enterprise value
- $3.14B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 69.1 10-yr median 22.0
- Price / book
- 4.0 10-yr median 2.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.17
TNGX key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTNGX valuation Price multiples at each fiscal year-end price.
Price / sales+105.6%
16.5
2025 · hover or tap a bar for each year
20192025
Price / book+75.8%
3.0
2025 · hover or tap a bar for each year
20192025
Free cash flow yield+25.6 pts
−13.6%
2025 · hover or tap a bar for each year
20192025
TNGX returns How much profit the business earns on the capital it uses.
Return on equity+20.3 pts
−37.2%
2025 · hover or tap a bar for each year
20192025
Return on assets+7.8 pts
−28.4%
2025 · hover or tap a bar for each year
20192025
Free cash flow margin+90.1 pts
−224.3%
2025 · hover or tap a bar for each year
20192025
Asset turnover+49.1%
0.17
2025 · hover or tap a bar for each year
20192025
TNGX per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+39.4%
$0.54
2025 · hover or tap a bar for each year
20192025
Earnings per share
−$0.87
2025 · hover or tap a bar for each year
20192025
Free cash flow per share
−$1.20
2025 · hover or tap a bar for each year
20192025
Book value per share+63.1%
$2.98
2025 · hover or tap a bar for each year
20192025
Shares outstanding+6.4%
116.2M
2025 · hover or tap a bar for each year
20192025
TNGX financial health Debt, liquidity and how easily interest is covered.
Debt / equity−47.0%
0.10
2025 · hover or tap a bar for each year
20192025
Net debt−$88.1M
−$309.6M
2025 · hover or tap a bar for each year
20192025
Current ratio+133.9%
16.32
2025 · hover or tap a bar for each year
20192025
Debt / assets−27.0%
0.08
2025 · hover or tap a bar for each year
20192025
TNGX efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding−98 days
223 days
2025 · hover or tap a bar for each year
20192025
Capex / revenue−0.1 pts
1.7%
2025 · hover or tap a bar for each year
20192025
TNGX valuation history
Fiscal year-endToday7-year median
TNGX returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TNGX debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TNGX price vs earnings per share
Share price at year-endEPS (right axis)
TNGX key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $1.03B | $337.5M | $936.3M | $636.7M | $679.5M | $1.00B | — |
| Enterprise value | $719.7M | $116.1M | $638.3M | $311.7M | $195.7M | $818.3M | — |
| Price / sales | 16.5 | 8.0 | 25.6 | 25.6 | 18.3 | 130.7 | — |
| Price / book | 3.0 | 1.7 | 3.7 | 2.6 | 2.0 | 25.9 | — |
| Price / free cash flow | — | — | — | — | — | 14.5 | — |
| Price / operating cash flow | — | — | — | — | — | 14.3 | — |
| EV / sales | 11.5 | 2.8 | 17.5 | 12.5 | 5.3 | 106.9 | — |
| EV / free cash flow | — | — | — | — | — | 11.9 | — |
| Earnings yield | −9.9% | −38.6% | −10.9% | −17.0% | −8.6% | −5.2% | — |
| Free cash flow yield | −13.6% | −39.2% | −12.8% | −18.3% | −9.0% | 6.9% | — |
| Shareholder yield (dividends + buybacks) | — | — | — | — | 0.0% | — | — |
| Share price at fiscal year-end | $8.86 | $3.09 | $9.90 | $7.25 | $10.94 | $11.44 | — |
| Per share | |||||||
| Revenue per share | $0.54 | $0.39 | $0.39 | $0.28 | $0.60 | $0.09 | $0.28 |
| Earnings per share | −$0.87 | −$1.19 | −$1.08 | −$1.23 | −$0.94 | −$0.59 | −$0.16 |
| Operating cash flow per share | −$1.20 | −$1.20 | −$1.25 | −$1.24 | −$0.96 | $0.80 | −$0.28 |
| Free cash flow per share | −$1.20 | −$1.21 | −$1.26 | −$1.33 | −$0.99 | $0.79 | −$0.30 |
| Cash per share | $2.95 | $2.36 | $3.56 | $4.17 | $7.81 | $2.18 | $0.46 |
| Book value per share | $2.98 | $1.83 | $2.68 | $2.84 | $5.55 | $0.44 | $0.09 |
| Tangible book value per share | $2.98 | $1.83 | $2.68 | $2.84 | $5.55 | $0.44 | $0.09 |
| Capex per share | $0.01 | $0.01 | $0.02 | $0.09 | $0.03 | $0.01 | $0.02 |
| Debt per share | $0.29 | $0.33 | $0.41 | $0.47 | $0.02 | $0.09 | $0.10 |
| Shares outstanding | 116.2M | 109.2M | 94.6M | 87.8M | 62.1M | 87.5M | 87.5M |
| Change in shares outstanding | +6.4% | +15.5% | +7.7% | +41.4% | −29.0% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −37.2% | −57.6% | −40.5% | −36.4% | −30.4% | −223.5% | −178.3% |
| Return on assets (ROA) | −28.4% | −36.2% | −24.3% | −23.1% | −16.5% | −39.5% | −25.3% |
| Return on tangible assets | −25.5% | −41.2% | −25.3% | −24.8% | −11.6% | −25.1% | −25.3% |
| Free cash flow margin | −224.3% | −314.4% | −327.2% | −469.7% | −165.7% | 900.8% | −108.0% |
| Financial health | |||||||
| Total debt | $33.6M | $36.5M | $38.9M | $41.1M | $1.5M | $7.9M | $8.5M |
| Cash & short-term investments | $343.1M | $257.9M | $336.9M | $366.1M | $485.3M | $190.3M | $40.4M |
| Net debt | −$309.6M | −$221.4M | −$298.0M | −$325.0M | −$483.8M | −$182.4M | −$31.9M |
| Debt / equity | 0.10 | 0.18 | 0.15 | 0.16 | 0.00 | 0.20 | 1.08 |
| Debt / assets | 0.08 | 0.12 | 0.10 | 0.09 | 0.00 | 0.04 | 0.15 |
| Current ratio | 16.32 | 6.98 | 7.54 | 6.76 | 12.10 | 4.73 | 1.61 |
| Quick ratio | 16.32 | 6.98 | 7.54 | 6.75 | 12.09 | 4.73 | 1.61 |
| Interest coverage | — | — | — | -37.7 | -50.9 | — | — |
| Working capital | $332.1M | $228.2M | $300.6M | $319.7M | $451.6M | $152.7M | $15.8M |
| Invested capital | $36.6M | −$21.9M | −$44.9M | −$75.5M | −$139.0M | −$143.8M | −$24.0M |
| Tangible asset value | $346.2M | $199.5M | $253.1M | $249.5M | $344.7M | $38.6M | $7.9M |
| Net current asset value | $301.2M | $149.4M | $197.1M | $188.3M | $336.9M | $25.0M | −$6.2M |
| Graham net-net per share | $2.50 | $1.29 | $1.98 | $2.06 | $5.34 | $0.26 | −$0.08 |
| Capital allocation | |||||||
| Share buybacks (net) | — | — | — | — | $0 | — | — |
| Capex / revenue | 1.7% | 1.8% | 4.2% | 30.9% | 5.0% | 14.4% | 7.4% |
| Capex / operating cash flow | — | — | — | — | — | 1.6% | — |
| Capex / depreciation | 0.46 | 0.30 | 0.63 | 4.78 | 2.05 | 1.54 | 2.83 |
| Stock-based compensation / revenue | 42.4% | 68.7% | 52.2% | 57.2% | 21.1% | 23.0% | 6.9% |
| R&D / revenue | 211.9% | 342.1% | 315.4% | 426.0% | 209.6% | 653.0% | 130.9% |
| SG&A / revenue | 66.5% | 104.0% | 97.2% | 120.8% | 47.5% | 128.9% | 30.6% |
| Efficiency | |||||||
| Days sales outstanding | — | — | 10.0 | 29.4 | 19.7 | 95.4 | — |
| Days of inventory on hand | — | — | — | 51.4 | 105.3 | — | — |
| Days payables outstanding | 222.7 | 320.3 | 11.5 | 347.9 | 470.4 | 282.0 | 7.6 |
| Cash conversion cycle (days) | — | — | -1.5 | -267.2 | -345.4 | -186.7 | — |
| Receivables turnover | — | — | 36.53 | 12.43 | 18.52 | 3.83 | — |
| Payables turnover | 1.64 | 1.14 | 31.83 | 1.05 | 0.78 | 1.29 | 48.17 |
| Inventory turnover | — | — | — | 7.10 | 3.47 | — | — |
| Asset turnover | 0.17 | 0.12 | 0.09 | 0.05 | 0.10 | 0.06 | 0.44 |
| Average receivables | — | — | $1.0M | $2.0M | $2.0M | $2.0M | — |
| Average payables | $1.4M | $2.2M | $3.6M | $3.8M | $2.5M | $1.3M | $670,000 |
| Average inventory | — | — | — | $567,000 | $567,000 | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from TNGX's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TNGX valuation and financial ratios
Tango Therapeutics earned a return on equity of −37.2% in fiscal 2025. It ended the year with $33.6 million of debt and $343.1 million in cash and short-term investments, a net cash position of $309.6 million. The share count rose 32.8% from 87.5M to 116.2M over 6 years.
See the TNGX income statement, the TNGX chart for price history, or the TNGX stock overview for the latest quote and news.
TNGX key metrics FAQ
What is Tango Therapeutics's return on equity?
Tango Therapeutics's return on equity (ROE) was −37.2% in fiscal 2025: net income of -$101.6 million on average shareholders' equity of $272.8 million.
How much debt does Tango Therapeutics have?
Tango Therapeutics had total debt of $33.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.10 and more cash than debt.
What is Tango Therapeutics's free cash flow yield?
Tango Therapeutics generated -$139.9 million of free cash flow in fiscal 2025, a free cash flow yield of −13.6% on its market value at year-end ($1.0 billion).
What is Tango Therapeutics's current ratio?
Tango Therapeutics's current ratio was 16.32 at the end of fiscal 2025: current assets were 16.32 times current liabilities.